Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future

Viking recently announced the results of an early-stage clinical trial for VK0214. Shares of pharmaceutical upstart Viking Therapeutics (VKTX 0.72%) have been soaring this year thanks to high hopes for VK2735, its promising GLP-1 weight loss treatment. Although the company doesn't have an approved product yet and isn't generating consistent revenue, the excitement around GLP-1 has been sufficient to send the stock's valuation north of $7 billion. Viking, however, is involved in more than just GLP-1 developm ...